Find a Clinical Trial

Showing 31 - 40 of 241 Trials

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator- Controlled Clinical Studyof Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumabin Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell

Principal Investigator:

Joshua R. Sonett, MD

Contact Number:

212-342-5162

NCT Number:

NCT06077760

Population:

Adult

Phase:

III

The purpose of this study is to evaluate the safety and effectiveness of the investigational drug V940 in combination with pembrolizumab for preventing relapse in non-small cell lung cancer. V940 is not yet approved by the U.S. Food and Drug Administration (FDA), which means it is still under investigation and has not been authorized for general use. Pembrolizumab, however, is an FDA-approved drug commonly used in cancer treatment. This study aims to determine how well V940 and pembrolizumab work together compared to a placebo combined with pembrolizumab. Additionally, it will assess the...
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA IT PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT06235151

Population:

Adult

Phase:

III

The purpose of this research study is to see how safe and effective the use of copper Cu 64 PSMA I&T Injection is in imaging prostate cancer tumors for staging of men with newly diagnosed intermediate or high risk prostate cancer. Copper Cu 64 PSMA I&T Injection is an investigational imaging agent, given to you through your vein (intravenous (IV)), that makes tumors from prostate cancer show up during a nuclear medicine imaging scan. The imaging scan is a type of nuclear medicine imaging test, which means it uses a radioactive drug (a drug that contains a radioactive substance and is...
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06346392

Population:

Adult

Phase:

III

The purpose of this study is to learn more about the effectiveness and safety of the study drug AZD0901 compared to standard therapy drugs (Ramucirumab, Paclitaxel, Docetaxel, Irinotecan, and TAS-102). AZD0901 is a type of drug known as an Antibody Drug Conjugate (abbreviated to ADC). AZD0901 recognizes cancer cells by specific protein called Claudin 18.2 (CLDN 18.2). CLDN 18.2 is one of the proteins that is expressed on the surface of gastric cancer cells. AZD0901 binds to CLDN 18.2 on the cancer surface and is taken into the cell where it releases the anti-cancer drug with the goal to stop...
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT06435429

Population:

Adult

Phase:

III

The purpose of this study is to find out whether zanidatamab combined with physician’s choice of chemotherapy (one of eribulin, gemcitabine, vinorelbine, or capecitabine) is safe and improves on the clinical benefit when compared to trastuzumab in combination with physician’s choice of chemotherapy (one of eribulin, gemcitabine, vinorelbine, or capecitabine) in treating the type of breast cancer you have, HER2-positive, metastatic (spread of cancer from the place where it started to other places in the body) breast cancer that is intolerant (drug is causing excessive side effects...
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator:

Gulam A. Manji, MD

Contact Number:

212-342-5162

NCT Number:

NCT06608927

Population:

Adult

Phase:

III

The purpose of this research is to determine the safety and efficacy of investigational study drug quemliclustat (also known as AB680) in combination with chemotherapy gemcitabine and nab-paclitaxel (Gem-NP), compared to a placebo (saline solution not containing treatment drug) in combination with chemotherapy gemcitabine and nab-paclitaxel at treating participants with the type of cancer you have. Quemliclustat has not been approved by the Food and Drug Administration (FDA). Gemcitabine and nab-paclitaxel (Gem-NP) is FDA approved but not in combination with quemliclustat. This is a double-...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune®(TTFields, 200 kHz) Concomitant with Maintenance Temozolomide andPembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide andPlacebo for the Treatment of Newly

Principal Investigator:

Fabio M. Iwamoto, MD

Contact Number:

212-342-5162

NCT Number:

NCT06556563

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects of pembrolizumab simultaneously with the Optune device and maintenance temozolomide (TMZ) versus placebo simultaneously with Optune and maintenance TMZ for the study treatment of newly diagnosed glioblastoma multiforme (GBM). In this study, a placebo is an inactive substance that looks the same as and is given the same way as pembrolizumab. The effects of pembrolizumab are compared to the effects of the placebo. Pembrolizumab is an immunotherapy and it works with your immune system to help fight cancer. Optune® device generates Tumor...
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH PREVIOUSLY TREATED KRAS G12C-POSITIVE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06497556

Population:

Adult

Phase:

III

The purpose of this study is to evaluate how well and how safely the experimental drug, divarasib, works compared to other approved drugs for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a mutation in the kirsten rat sarcoma virus (KRAS) G12C gene. This gene mutation drives cancer growth. The other approved treatments are sotorasib or adagrasib. The study drug, divarasib, is experimental, meaning it has not yet been approved by the U.S. Food and Drug Administration. While several drugs targeting this gene mutation have recently been developed, there is still...
A Multinational, Multicenter, Prospective, Open-Label, Dosimetry and Safety Study of Lutetium (177Lu) rosopatamab tetraxetan in Combination with Standard of Care in Patients with PSMA Positive Metastatic Castration-Resistant Prostate Cancer after Androgen

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT06520345

Population:

Adult

Phase:

III

This study aims to explore a possible new treatment for advanced prostate cancer that has spread to other parts of the body and tests positive for a specific protein called PSMA (prostate-specific membrane antigen). This treatment involves a special drug that seeks out cancer cells by recognizing PSMA on their surface. The drug combines an antibody— a molecule that can find and attach to specific targets on cancer cells—with a radioactive component. Once attached, it delivers radiation directly to the cancer cells to help destroy them. The drug being studied is called 177Lu-TLX591...
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)

Principal Investigator:

David P. Horowitz, MD

Contact Number:

212-342-5162

NCT Number:

NCT05673148

Population:

Adult

Phase:

III

For patients with your stage of metastatic colorectal cancer, ablative local therapy (ALT) is commonly used to treat all known tumor sites. ALT may be performed by surgery, radiation therapy, heat with microwave ablation, or other methods. This study will use radiation therapy and potentially surgery and/or heat. The use of ALT in addition to your usual treatment could shrink your cancer and prevent it from returning. Although it is common to use ALT, at this time, it is not scientifically proven that the addition of ALT is beneficial for your stage of cancer. The purpose of this study is to...
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Principal Investigator:

Andrew H Lipsky, MD

Contact Number:

212-342-5162

NCT Number:

NCT04662255

Population:

Adult

Phase:

III

This research study is being done to test the effectivenss and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or “addicted to” a protein made by the cancers called “BTK”. LOXO-305 is a “BTK inhibitor”—it is designed to block both normal and mutated forms of BTK in these cancers. Are you Eligible? (Inclusion Criteria) At least 18 years of age Able to swallow oral...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages